Biotinylated Human CD20/MS4A1 Protein
Catalog No: CD20-HB005
- Species
- Human
- Expression System
- E.coli
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD20/MS4A1 Protein is expressed in E. coli with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ile141-Ser188 (UniProt accession: P11836-1).
Product Details
- Molecular Aliases
- MS4A1; CD20; MS4A-1; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 11; Leukocyte surface antigen Leu16
- Protein Length
- Ile141-Ser188
- Expression System
- E.coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 16.8 kDa same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22μm filtered solution in 20mM PB, 500mM NaCl, 0.4M Urea, 10% glycerol, 1mM GSH, 0.1mM GSSG (pH 7.0).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Human CD20 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Biotinylated Human CD20, His-Avi tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.13μg/ml determined by ELISA (QC Test).
Loaded Biotinylated Human CD20, His-Avi tag on Steptavidin-Biosensor can bind Anti-CD20 Antibody, hFc Tag with an affinity constant of 0.15 μM as determined in BLI assay.
Background
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R, CD117) and progressively increasing in concentration until maturity. CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
References
- Ma D, Mcdevitt M R, Barendswaard E, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66.
- Jager U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.